Bayer looking for a "mid-size M&A transaction" in oncologyJune 13, 2023 - ' Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.'
https://www.fiercepharma.com/pharma/bayer-needs-midsize-acquisition-reach-10b-cancer-drug-sales-goal-oncology-chief-says
As for modalities, Bayer has identified precision molecular oncology, next-generation immuno-oncology medicines and radioligand therapies as its top priorities.
Having an ambition to join the ranks of the top cancer drug makers motivates the organization. But to Roth, becoming a top oncology player isn’t just about the statistics but rather building a business to have a bigger impact on patient care.
In another boon to Bayer’s oncology ambitions, a pharma veteran with deep oncology experience just arrived as the helmsman of the entire Bayer group. Bill Anderson, most recently Roche’s pharma chief, officially became Bayer's CEO on June 1.